YahooAugust 13, 2026 at 3:04 PM NY22 days ago

Valneva Q2 Earnings Call Highlights

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Read at Source

Companies in This Story

PFEPfizer Inc28.39− 1.46%

Companies in This Story

Related Stories